Sanofi plans to build a world class vaccine production site and a new research centre dedicated for the development of vaccines with an investment of €610 million.
Evolutive Vaccine Facility (EVF), the plant in Neuville sur Saône, will make use of the latest advanced vaccine production technologies. The new facility with an investment of €490 will allow securing vaccine supplies in case of pandemic outbreaks. In addition, another €120 million is invested to design a new R&D centre.
The new facility consists of a central unit for housing various fully digital production modules that facilitate production of three to four vaccines simultaneously. In addition, it consists of specialised laboratories for development of vaccines against emerging diseases and pandemic risks,thus becoming a world reference for pre-clinical research and, pharmaceutical and clinical development.
The facility will create 200 new job opportunities while the new production line will strengthen Sanofi’s capacity to invent new vaccines there by meeting public health issues.